New Results
Turning high-throughput structural biology into predictive inhibitor design
View ORCID ProfileKadi L. Saar, Daren Fearon, The COVID Moonshot Consortium, View ORCID ProfileFrank von Delft, View ORCID ProfileJohn D. Chodera, Alpha A. Lee
doi: https://doi.org/10.1101/2021.10.15.464568
Kadi L. Saar
1Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK
2Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge CB3 0HE, UK
Daren Fearon
3Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK
Frank von Delft
3Diamond Light Source Ltd., Harwell Science and Innovation Campus, Didcot, UK
4Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Headington, OX3 7DQ, UK
John D. Chodera
5Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Alpha A. Lee
2Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge CB3 0HE, UK
6PostEra Inc, 2 Embarcadero Center, San Francisco, CA 94111, USA
Posted October 15, 2021.
Turning high-throughput structural biology into predictive inhibitor design
Kadi L. Saar, Daren Fearon, The COVID Moonshot Consortium, Frank von Delft, John D. Chodera, Alpha A. Lee
bioRxiv 2021.10.15.464568; doi: https://doi.org/10.1101/2021.10.15.464568
Subject Area
Subject Areas
- Biochemistry (11740)
- Bioengineering (8750)
- Bioinformatics (29189)
- Biophysics (14967)
- Cancer Biology (12093)
- Cell Biology (17410)
- Clinical Trials (138)
- Developmental Biology (9420)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18301)
- Genetics (12239)
- Genomics (16797)
- Immunology (11865)
- Microbiology (28070)
- Molecular Biology (11583)
- Neuroscience (60953)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4957)
- Plant Biology (10425)
- Synthetic Biology (2884)
- Systems Biology (7338)
- Zoology (1651)